个体化舌下含服药物治疗尘螨过敏性鼻炎的有效性及安全性分析  

Analysis of effectiveness and safety of individualized sublingual medication in the treatment of dust mite allergic rhinitis

作　　者：刘世国 

机构地区：[1]汕尾市人民医院,516600

出　　处：《中国现代药物应用》2017年第20期100-102,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨个体化舌下含服药物治疗尘螨过敏性鼻炎的有效性及安全性。方法单一过敏原和多重过敏原的尘螨过敏性鼻炎患者各500例作为研究对象,设为单一过敏组和多重过敏组,将两组分别利用随机数字表分为正常用药组和个体化组,各250例。两个正常用药亚组均分别给予常规治疗,两个个体化组均分别给予个体化舌下含服特异性免疫治疗。对比单一过敏组和多重过敏组中不同亚组的临床效果和安全性。结果单一过敏组中个体化组治疗后症状评分、用药评分、体征评分和视觉模拟评分(VAS)评分均远低于正常用药组,差异具有统计学意义(P<0.05)。单一过敏组中个体化组总有效率为97.20%,明显高于正常用药组的89.20%,差异具有统计学意义(χ2=12.623,P<0.05)。多重过敏组中个体化组治疗后症状评分、用药评分、体征评分和VAS评分均远低于正常用药组,差异具有统计学意义(P<0.05)。多重过敏组中个体化组总有效率为96.40%,明显高于正常用药组的88.00%,差异具有统计学意义(χ2=12.264,P<0.05)。单一过敏组中,个体化组不良反应发生率为0,明显低于正常用药组的2.80%,差异具有统计学意义(χ2=7.099,P<0.05);多重过敏组中,个体化组不良反应发生率为0,明显低于正常用药组的3.60%,差异具有统计学意义(χ2=9.165,P<0.05)。结论对尘螨过敏性鼻炎患者实施个体化舌下含服药物治疗效果理想,能够显著控制症状,改善体征,减轻疼痛,且安全性均较高,值得推广。Objective To investigate the effectiveness and safety of individualized sublingual medication in the treatment of dust mite allergic rhinitis. Methods A total of 500 dust mite allergic rhinitis patients caused by single allergen and multiple allergens as study subjects were named as single allergen group and multiple allergen group. Both groups were divided by random number table method into normal medication group and individualized group, with 250 cases in each group. Two normal medication groups received conventional therapy, and two individualized group received individualized sublingual immunotherapy. Comparison were made on clinical effect and safety of different subgroups in single allergen group and multiple allergen group. Results In single allergen group, individualized group had lower symptom score, medication score, physical sign score and visual analogue scale（VAS） score after treatment than normal medication group, and the difference was statistically significant（P〈0.05）. Individualized group had obviously higher total effective rate as 97.20% than 89.20% in normal medication group, and their difference was statistically significant（χ^2=12.623, P〈0.05）. In multiple allergen group, individualized group had lower symptom score, medication score, physical sign score and VAS score after treatment than normal medication group, and the difference was statistically significant（P〈0.05）. Individualized group had obviously higher total effective rate as 96.40% than 88.00% in normal medication group, and the difference was statistically significant（χ^2=12.264, P〈0.05）. In single allergen group, individualized group had obviously lower incidence of adverse reactions as 0 than 2.80% in normal medication group, and the difference was statistically significant（χ^2=7.099, P〈0.05）. In multiple allergen group, individualized group had obviously lower incidence of adverse reactions as 0 than 3.60% in normal medication group, and the difference was statistically significant（χ^2=9

关 键 词：个体化疗法 舌下含服药物 尘螨过敏性鼻炎 有效性 安全性 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]